Biohaven Ltd. 8-K

What Happened

• Biohaven Ltd. filed an 8-K on May 4, 2026 reporting results from its April 28, 2026 Annual Meeting of shareholders. All board nominees were elected and shareholders approved ratification of the company’s independent auditor and the advisory vote on executive compensation.
• Director vote totals:
  • Michael T. Heffernan: 76,133,746 For; 15,092,665 Against; 1,984,918 Abstained
  • Irina Antonijevic, M.D., Ph.D.: 76,612,017 For; 14,616,115 Against; 1,983,197 Abstained
  • Robert J. Hugin: 76,597,707 For; 14,626,151 Against; 1,987,471 Abstained
  • Broker non-votes for director elections: 32,137,064
• Auditor ratification and say-on-pay:
  • Ratification of Ernst & Young LLP as auditor: 123,723,636 For; 214,123 Against; 1,410,634 Abstained (approved)
  • Advisory (non-binding) vote on named executive officer compensation: 87,521,620 For; 4,202,883 Against; 1,486,826 Abstained; broker non-votes: 32,137,064 (approved)

Key Details

• Annual Meeting date: April 28, 2026; 8-K filed May 4, 2026 (Item 5.07).
• All director nominees (Heffernan, Antonijevic, Hugin) elected for terms expiring at the 2029 annual meeting.
• Ernst & Young LLP ratified as independent auditor for fiscal year ending Dec 31, 2026.
• Advisory "say-on-pay" vote approved by a large majority of votes cast (non-binding).

Why It Matters

• Board continuity: Election of the nominated directors confirms the company’s current board slate through 2029, which affects governance and oversight continuity.
• Audit continuity: Ratification of Ernst & Young provides assurance of continuity in independent financial review for FY 2026.
• Shareholder approval of executive pay: The approved advisory vote indicates shareholder support for the company’s compensation approach (though it is non-binding). Large broker non-votes on certain items reflect shares held by brokers that did not vote on those matters.